Products / Services
  • Products / Services
  • Companies
  • Buy Leads
Post Buy Requirement

Sunitinib Malate Capsules

Listing ID #6529941

  • StorageCool and Dry Place
  • FormCapsules
  • DosageAs per Doctor's Prescription
  • TreatmentUsed to Treat Adults with Certain Types of Gastrointestinal Stromal Tumors,
  • Best Before36 Months from Manufacturing
  • Supply Type Supplier
  • Preferred Buyer Location All over the world
Send Enquiry

Company Information

  • Member Since 2 Years
  • Nature of Business Exporter
  • GST No. 07ABEFM6994Q2Z7

Ask for more detail from the seller

Contact Supplier

Product Details no_img_icon

On November 16, 2017, the Food and Drug Administration approved sunitinib malate for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.On November 16, 2017, the Food and Drug Administration approved sunitinib malate (Sutent, Pfizer Inc.) for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.Sunitinib malate capsules belongs to a class of drugs called Antineoplastics, Tyrosine Kinase Inhibitor; Antineoplastics, VEGF Inhibitor.

 

A drug used to treat adults with certain types of gastrointestinal stromal tumors, pancreatic neuroendocrine tumors, or renal cell carcinoma (a type of kidney cancer). It is also being studied in the treatment of other types of cancer. Sunitinib malate blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Sunitinib malate is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Sunitinib is the active ingredient of sunitinib malate. Also called SU011248, SU11248, and Sutent. US Brand Name(s): Sutent. FDA Approved: Yes

 

Sunitinib, sold under the brand name Sutent, is a medication used to treat cancer. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.

 

Sunitinib malate is approved to treat adults with:

  • Gastrointestinal stromal tumor (a type of stomach cancer). It is used in patients whose condition has become worse while taking imatinib mesylate or who are not able to take it.
  • Pancreatic cancer. It is used in patients with progressive neuroendocrine tumors that cannot be removed by surgery, are locally advanced, or have metastasized (spread to other parts of the body).
  • Renal cell carcinoma (a type of kidney cancer).
  • Sunitinib malate is also being studied in the treatment of other types of cancer.


Company Details close-icon

Established in 2016, Medicant Healthcare has secured a noticeable position among the Exporter and service providers of good quality Pharmaceutical Medicines and Cancer Drugs. Our drugs are designed following the FDA norms under the strict supervision of qualified experts. Our product range comprises Ulcerative Colitis, Uterus Cancer, Thyroid Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Kidney Cancer, Gastric Cancer, Immunology, and Colorectal Cancer. Known for their fast and long-lasting results, these drugs are rather demanded around the world.

For the secure and hygienic design of the available drugs, we have established a roomy infrastructure, which is further segregated into numerous departments. The departments are capable of advanced machines, which are upgraded according to the present market demands.

A well-maintained warehouse makes sure useful storage of the offered products. According to the vast and trustworthy logistic partners, we bring our products to the customer’s end within the set time frame. Moreover, our drugs are made available at an affordable market cost.

Our revered mentors, Mr. Akhilesh Chaudhary, motivate the team with their rich industry knowledge and experience. The prime focus is on offering a smooth and pressure-free work setting for the employees and has assisted them to give their best. Additionally, they have enabled the company in gaining a strong market stand among the manufacturers and suppliers of excellent quality pharmaceutical medicines and cancer drugs.

  • Nature of Business Exporter / Service Provider / Supplier
  • Number of Employees Below 20
  • Year of Establishment 2016
Tell us your Buy Requirement to Get Instant Response
Tell us what you need?

By clicking Get Quotes Now, I accept the T&C and Privacy Policy.

Looking for Sunitinib Malate Capsules?

Quantity
Seller Contact Details
Waiting for permission
To search by voice, go to your browser settings and allow access to microphone

Allow microphone access to search with voice